Lyra

Lyra Therapeutics develops long-acting, bioabsorbable nasal implants delivering mometasone furoate to treat chronic rhinosinusitis for up to six months.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2020
Stage of Initial Investment
Series B
Initial Investment Year
2018